## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20049	

OMB APPR	OVAL				
OMB Number:	3235-0287				
Estimated average but	rden				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(0). 0	ee instruction	10.																		
Name and Address of Reporting Person*     Beskrovnaya Oxana					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Dyne Therapeutics, Inc. [DYN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
DCSKIU	viiaya Oz	<u>varia</u>			`					-	-				Direc			10% O\	-	
,					<u> </u>									1	Office	er (give title		Other (s	specify	
(Last)	(Fi	rst) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year)									Chief Scientific Officer						
C/O DYNE THERAPEUTICS, INC.					09/11/2024									Chief Scientific Officer						
1560 TR	APELO RO	OAD																		
					4. If Amendment, Date of Original Filed (Month/Day/Year)								, 1	6. Individual or Joint/Group Filing (Check Applicable						
(Street)						1. If Alliendrich, Date of Original Filed (World Day) Teal)									Line)					
WALTH.	AM M	Δ 0	2451											Form filed by One Reporting Person					on	
WILLIII	7 X 1 V 1 1 V 1	71 0	2431											Form filed by More than One Reporting					orting	
															Perso	on				
(City)	(St	ate) (Z	Zip)																	
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quirec	d, Dis	posed of	, or E	Benefic	cially	<b>Own</b>	ed				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				Execution (Year) if any				3. Transaction Code (Instr. 8)					and 5) Securi Benefi Owner		rities   I ficially   ( ed Following   (		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 09/11/20				024				<b>S</b> <sup>(1)</sup>		2,161	D	\$31.	89(2)	9(2) 142,714(3)			D			
		Tal	ble II								osed of, convertib				Owne	d				
	1	1	_			4110, 1			_					<del>-</del>					1	
1. Title of Derivative Security (Instr. 3)	Security or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Dei Sed (Ins	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares							

## **Explanation of Responses:**

- 1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$31.59 to \$32.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- 3. Includes 114,885 unvested RSUs

/s/ Richard Scalzo, Attorney-

09/11/2024

in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.